Showing results (41-50 of 725) with videos related to

Sort By:
Pageof 73
Deutsche Medizinische Wochenschrift (1946)|December 4, 1992
[Patent foramen ovale and platypnea after pneumonectomy]J Buss, V Grimm, K Huck, et al.
Gynecologic and Obstetric Investigation|January 12, 2000
Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudinG Huhle, M Geberth, U Hoffmann, et al.
Deutsche Medizinische Wochenschrift (1946)|November 30, 1984
[Lorcainide in stable ventricular extrasystole. A double-blind study with 48-hour continuous ECG recording]J Buss, B Stegaru, S Geiger, et al.
American Journal of Veterinary Research|July 1, 1996
Preferential binding of heparin to granulocytes of various speciesJ Harenberg, R Malsch, L Piazolo, et al.
Thrombosis and Haemostasis|December 22, 1988
Monitoring of heparin and low molecular weight heparin with capillary and venous whole bloodJ Harenberg, C Giese, C E Dempfle, et al.
Annals of the New York Academy of Sciences|June 18, 1999
Evaluation of systolic performance by automated impedance cardiographyA W Scherhag, J Stastny, S Pfleger, et al.
Thrombosis and Haemostasis|December 20, 1993
Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparinsJ Harenberg, M Siegele, C E Dempfle, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1997
Anticoagulation in patients with heparin-induced thrombocytopenia type IIJ Harenberg, G Huhle, L Piazolo, et al.
European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1987
Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activityR Elfner, G Achtert, H J Hausleiter, et al.
Thrombosis and Haemostasis|June 30, 1989
Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteersJ Harenberg, C Giese, C E Dempfle, et al.
Pageof 73